SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: Kevin Hamlin who wrote (993)11/10/1998 1:48:00 PM
From: Wisee  Respond to of 1185
 
To All,

Bob Rieder, CEO of Nortran, states in his shareholder's letter dated Oct. 20/98:
"We are delighted to welcome Mr. Joseph Rus aboard, as our new Senior Director of Business Development. Mr. Rus, who most recently worked with F. Hoffman-LaRoche, brings over 25 years of international pharmaceutical industry experience to Nortran Pharmaceuticals, and will be responsible for all partnering and in-licensing activities".

This is great news for Nortran.

One has to ask, why would Mr. Rus quit (I presume) a comfortable job at Hoffman-LaRoche to join Nortran.
Does he know something that we don't??

Wisee




To: Kevin Hamlin who wrote (993)11/11/1998 8:36:00 AM
From: chevalier  Read Replies (1) | Respond to of 1185
 
NRT is moving simply because biotech stocks are smoking hot in N. America at the moment. The percentage move in NRT is very small compared to most others. Most biotech stocks on the TSE are near doubles from their lows in early October.
The only piece of news that would really effect NRT would be another deal with a Euro major. The team had been in Europe for a while so something may be in the works here?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News